Reducing Intracranial atheroSclErosis With Repatha
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study will be to understand the underlying mechanism by which PCSK9
inhibition reduces the rate of ischemic stroke seen in the pivotal studies that led to its
FDA approval for ASCVD such as ischemic stroke. Those trials (FOURIER and ODYSSEY) enrolled
almost 50,000 patients and showed that PCSK9 inhibition therapy is safe and effective. The
investigators hypothesize that PCSK9 inhibition lowers the rate of stroke by reducing
atherosclerotic plaque, which would be particularly beneficial for patients with intracranial
atherosclerosis, who have the highest rate of recurrent stroke of any stroke mechanism.